CA2855359A1 - Procedes et compositions utilisant de la 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-piperidine-2,6-dione, un agent d'alkylation n-moutarde et du prednisone pour le traitement etla gestion du myelome multiple - Google Patents

Procedes et compositions utilisant de la 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-piperidine-2,6-dione, un agent d'alkylation n-moutarde et du prednisone pour le traitement etla gestion du myelome multiple Download PDF

Info

Publication number
CA2855359A1
CA2855359A1 CA2855359A CA2855359A CA2855359A1 CA 2855359 A1 CA2855359 A1 CA 2855359A1 CA 2855359 A CA2855359 A CA 2855359A CA 2855359 A CA2855359 A CA 2855359A CA 2855359 A1 CA2855359 A1 CA 2855359A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
stereoisomer
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2855359A
Other languages
English (en)
Inventor
Jerome B. Zeldis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority claimed from CA2727830A external-priority patent/CA2727830C/fr
Publication of CA2855359A1 publication Critical patent/CA2855359A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
CA2855359A 2002-05-17 2003-05-16 Procedes et compositions utilisant de la 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-piperidine-2,6-dione, un agent d'alkylation n-moutarde et du prednisone pour le traitement etla gestion du myelome multiple Abandoned CA2855359A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38084202P 2002-05-17 2002-05-17
US60/380,842 2002-05-17
US42460002P 2002-11-06 2002-11-06
US60/424,600 2002-11-06
CA2727830A CA2727830C (fr) 2002-05-17 2003-05-16 Methodes et compositions utilisant du 3-(4-amino-1-oxo-1,3-dihydro-isoinndol-2-yl)-piperidine-2,6-dione pour letraitement et la gestion de myel omes multiples

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2727830A Division CA2727830C (fr) 2002-05-17 2003-05-16 Methodes et compositions utilisant du 3-(4-amino-1-oxo-1,3-dihydro-isoinndol-2-yl)-piperidine-2,6-dione pour letraitement et la gestion de myel omes multiples

Publications (1)

Publication Number Publication Date
CA2855359A1 true CA2855359A1 (fr) 2003-11-27

Family

ID=49449200

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2855306A Abandoned CA2855306A1 (fr) 2002-05-17 2003-05-16 Methodes et compositions utilisant du 3-(4-amino-1-oxo-1,3-dihydro-isoinndol-2-yl)-piperidine-2,6-dione pour letraitement et la gestion de myel omes multiples
CA2855359A Abandoned CA2855359A1 (fr) 2002-05-17 2003-05-16 Procedes et compositions utilisant de la 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-piperidine-2,6-dione, un agent d'alkylation n-moutarde et du prednisone pour le traitement etla gestion du myelome multiple

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2855306A Abandoned CA2855306A1 (fr) 2002-05-17 2003-05-16 Methodes et compositions utilisant du 3-(4-amino-1-oxo-1,3-dihydro-isoinndol-2-yl)-piperidine-2,6-dione pour letraitement et la gestion de myel omes multiples

Country Status (4)

Country Link
CA (2) CA2855306A1 (fr)
DK (1) DK2105135T3 (fr)
NZ (1) NZ595125A (fr)
SI (1) SI2105135T1 (fr)

Also Published As

Publication number Publication date
CA2855306A1 (fr) 2003-11-27
SI2105135T1 (sl) 2015-01-30
DK2105135T3 (da) 2014-11-03
NZ595125A (en) 2013-10-25

Similar Documents

Publication Publication Date Title
US10206914B2 (en) Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
CA2727830A1 (fr) Methodes et compositions utilisant du 3-(4-amino-1-oxo-1,3-dihydro-isoinndol-2-yl)-piperidine-2,6-dione pour letraitement et la gestion de myel omes multiples
USRE48890E1 (en) Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
CA2855359A1 (fr) Procedes et compositions utilisant de la 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-piperidine-2,6-dione, un agent d'alkylation n-moutarde et du prednisone pour le traitement etla gestion du myelome multiple

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140626

FZDE Dead

Effective date: 20170914